Blonanserin
Code | Size | Price |
---|
TAR-T1180-5mg | 5mg | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1180-10mg | 10mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1180-25mg | 25mg | £139.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1180-50mg | 50mg | £172.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1180-100mg | 100mg | £211.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1180-200mg | 200mg | £324.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.
CAS:
132810-10-7
Formula:
C23H30FN3
Molecular Weight:
367.512
Pathway:
GPCR/G Protein; Neuroscience
Purity:
1
SMILES:
CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1
Target:
Dopamine Receptor; Sigma receptor; 5-HT Receptor; Adrenergic Receptor
References
1. Ohoyama K, et al. Eur J Pharmacol,2011, 653(1-3), 47-57.
2. Huang M, et al. J Neurochem,2014, 128(6), 938-949.
3. Baba S, et al. J Pharmacol Sci,2015, 127(3), 326-331.
4. Inoue T, et al. Prog Neuropsychopharmacol Biol Psychiatry,2012, 39(1), 156-162.
5. Horiguchi M, et al. Behav Brain Res,2013, 247, 158-164.